249 related articles for article (PubMed ID: 17716840)
1. Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir.
Palmberger TF; Hombach J; Bernkop-Schnürch A
Int J Pharm; 2008 Feb; 348(1-2):54-60. PubMed ID: 17716840
[TBL] [Abstract][Full Text] [Related]
2. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein.
Föger F; Hoyer H; Kafedjiiski K; Thaurer M; Bernkop-Schnürch A
Biomaterials; 2006 Dec; 27(34):5855-60. PubMed ID: 16919723
[TBL] [Abstract][Full Text] [Related]
3. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan.
Föger F; Schmitz T; Bernkop-Schnürch A
Biomaterials; 2006 Aug; 27(23):4250-5. PubMed ID: 16618504
[TBL] [Abstract][Full Text] [Related]
4. Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system.
Hombach J; Hoyer H; Bernkop-Schnürch A
Eur J Pharm Sci; 2008 Jan; 33(1):1-8. PubMed ID: 17980561
[TBL] [Abstract][Full Text] [Related]
5. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats.
Krauland AH; Guggi D; Bernkop-Schnürch A
J Control Release; 2004 Mar; 95(3):547-55. PubMed ID: 15023465
[TBL] [Abstract][Full Text] [Related]
6. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine.
Werle M; Hoffer M
J Control Release; 2006 Mar; 111(1-2):41-6. PubMed ID: 16377016
[TBL] [Abstract][Full Text] [Related]
7. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor.
Iqbal J; Hombach J; Matuszczak B; Bernkop-Schnürch A
J Control Release; 2010 Oct; 147(1):62-9. PubMed ID: 20603165
[TBL] [Abstract][Full Text] [Related]
8. Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide.
Iqbal J; Shahnaz G; Perera G; Hintzen F; Sarti F; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2012 Jan; 80(1):95-102. PubMed ID: 21964316
[TBL] [Abstract][Full Text] [Related]
9. Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system.
Bernkop-Schnürch A; Guggi D; Pinter Y
J Control Release; 2004 Jan; 94(1):177-86. PubMed ID: 14684281
[TBL] [Abstract][Full Text] [Related]
10. Thiolated chitosan microparticles: a vehicle for nasal peptide drug delivery.
Krauland AH; Guggi D; Bernkop-Schnürch A
Int J Pharm; 2006 Jan; 307(2):270-7. PubMed ID: 16300914
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: in vitro evaluation in intestinal epithelial cells (Caco-2).
Kotzé AF; Thanou MM; Luebetaen HL; de Boer AG; Verhoef JC; Junginger HE
J Pharm Sci; 1999 Feb; 88(2):253-7. PubMed ID: 9950647
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique.
Fortuna A; Alves G; Falcão A; Soares-da-Silva P
Epilepsia; 2012 Mar; 53(3):529-38. PubMed ID: 22372629
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption.
Rekha MR; Sharma CP
J Control Release; 2009 Apr; 135(2):144-51. PubMed ID: 19331862
[TBL] [Abstract][Full Text] [Related]
14. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
15. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.
Sadeghi AM; Dorkoosh FA; Avadi MR; Weinhold M; Bayat A; Delie F; Gurny R; Larijani B; Rafiee-Tehrani M; Junginger HE
Eur J Pharm Biopharm; 2008 Sep; 70(1):270-8. PubMed ID: 18492606
[TBL] [Abstract][Full Text] [Related]
16. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine.
Okudaira N; Komiya I; Sugiyama Y
J Pharmacol Exp Ther; 2000 Nov; 295(2):717-23. PubMed ID: 11046110
[TBL] [Abstract][Full Text] [Related]
17. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs.
Sha X; Fang X
Int J Pharm; 2004 Mar; 272(1-2):161-71. PubMed ID: 15019079
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells.
Thomsen AE; Christensen MS; Bagger MA; Steffansen B
Eur J Pharm Sci; 2004 Dec; 23(4-5):319-25. PubMed ID: 15567284
[TBL] [Abstract][Full Text] [Related]
19. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan.
Föger F; Kafedjiiski K; Hoyer H; Loretz B; Bernkop-Schnürch A
J Drug Target; 2007 Feb; 15(2):132-9. PubMed ID: 17365284
[TBL] [Abstract][Full Text] [Related]
20. Frog intestinal sac as an in vitro method for the assessment of intestinal permeability in humans: Application to carrier transported drugs.
Franco M; Lopedota A; Trapani A; Cutrignelli A; Meleleo D; Micelli S; Trapani G
Int J Pharm; 2008 Mar; 352(1-2):182-8. PubMed ID: 18055143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
